Health products and supplements can be extremely valuable to people with cancer, but new research has found they can also be potentially harmful.
Key points:In the latest study, researchers at the University of Exeter looked at a cancer drug called Bupivacil for melanomas.
The drug was approved in June for use in melanoma and had a safety profile of low toxicity.
But in October, the UK Health Protection Agency (HPA) suspended approval of the drug after reports that it may cause serious side effects, including kidney failure, bleeding and infections.
“I am a strong supporter of the HPA decision, but it does come with a number of challenges.
First, the drug is still undergoing clinical trials, and the company is now in the process of reviewing the safety data.
Second, the approval process itself is complex and complex,” Professor Andrew Burch of the University’s Department of Epidemiology and Health Science said.”
It is possible that this process is not as clear as we might have hoped.”
He said a lack of clinical data could hamper the process, and that the Hpa’s decision to suspend the drug was based on “lack of evidence” about its safety.
“We have a number other potentially problematic drugs on the market, which we have been working on to try and address the issues around toxicity, and safety, and efficacy,” Professor Burch said.
He said while the drug had been approved in the UK, other countries had had “lots of difficulties” with the approval of Bupilacil, including a ban on its sale to patients in Mexico.
“There are some countries that have not had the experience that we have had in Mexico and we don’t want to have a similar experience here in the US,” Professor Brett Hickey said.
The drug has been approved for use as a treatment for melanosarcoma in melanomas in patients who have been treated with other types of cancer treatments, but is currently available in a limited number of US states and has not been approved by the US Food and Drug Administration (FDA).
Bupivaceil has been licensed to Genentech, a biopharmaceutical company based in Menlo Park, California, since September 2015, and has received approval to be marketed in Europe.
It was approved for the treatment of metastatic melanoma in melanosarcophagia in humans.
“The HPA suspension decision is a disappointment to many of us, and we have to be very, very careful about the word ‘disappointment’,” Professor Hickey added.
“This drug is not only important to patients with melanoma, it’s also important to our entire melanoma research community and for melanogen-enhancing therapies in general.”
A suspension is a big disappointment for us, but we’re going to take it on faith that this drug will come out of the review process.
“Professor Hickey also said that he expected the UK to move on with Bupavacil after the Hpas decision was announced.”
My view is that this is a very positive moment for Bupacil,” he said.
Professor Hoch said there were other drugs available to treat melanoma that had not been shown to be safe and effective in humans, and Bupapacil could potentially be an exception.”
That’s a major concern, because we’ve only got about 20 to 30 years of experience with this drug in melanocancers, so we’re still at the very beginning stages of understanding how this drug works in melanoaces,” he added.
Professor Brett Hoch, director of the Department of Cancer Epidemiology & Genetics, said there was no reason why Bupvacil should not be approved for sale in Europe, and he was hopeful that a decision on its merits would be made in the coming months.”
Bupvapacol has not had a drug approval in the European Union, so the likelihood of Bups being approved in Europe is a strong possibility, although I’m not sure it’s a given that this will happen in the next two years,” he explained.
He also highlighted the need for greater public education about the health benefits of vitamin C and other antioxidants in order to promote uptake.”
People need to be aware of the fact that there are other supplements that contain vitamin C, like the sunscreens and vitamin D-rich products, but I do believe we need to educate people about the benefits of these supplements, particularly in the context of melanoma,” Professor Hoch added.